Sarcoma — Trials · CancerIndex

Clinical trials

Registered studies

2,688 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 635
Recruiting: 365
Ph III recruiting: 20
Growth YoY: −15.2%
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (367)

clinicaltrialsPublishedShowing 401–450 of 2,688 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05301764	A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma	completed	Phase 1 / Phase 2	39	Lyvgen Biopharma Holdings LimitedINDUSTRY	1	May 20, 2026	clinicaltrials
NCT03643133	Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients(SARCOME13)	active not recruiting	Phase 2	60	UNICANCEROTHER	1	May 19, 2026	clinicaltrials